218 related articles for article (PubMed ID: 34583518)
1. PROTAC cell permeability and oral bioavailability: a journey into uncharted territory.
Poongavanam V; Kihlberg J
Future Med Chem; 2022 Jan; 14(3):123-126. PubMed ID: 34583518
[No Abstract] [Full Text] [Related]
2. The application of ubiquitin ligases in the PROTAC drug design.
Chen Y; Jin J
Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):776-790. PubMed ID: 32506133
[TBL] [Abstract][Full Text] [Related]
3. Special Focus Issue - Targeted protein degradation: a new paradigm in medicinal chemistry.
Wall H
Future Med Chem; 2022 Jan; 14(3):115-117. PubMed ID: 35080920
[No Abstract] [Full Text] [Related]
4. Proteolysis-targeting chimeras: a kaleidoscope of targeted protein degradation.
Mou Y; Wen S; Gao X; Jiang ZY
Future Med Chem; 2022 Jan; 14(3):139-141. PubMed ID: 34814705
[No Abstract] [Full Text] [Related]
5. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
6. The Present and Future of Novel Protein Degradation Technology.
Xia L; Liu W; Song Y; Zhu H; Duan Y
Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
[TBL] [Abstract][Full Text] [Related]
7. Arvinas's PROTACs pass first safety and PK analysis.
Mullard A
Nat Rev Drug Discov; 2019 Nov; 18(12):895. PubMed ID: 31780851
[No Abstract] [Full Text] [Related]
8. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation.
Jevtić P; Haakonsen DL; Rapé M
Cell Chem Biol; 2021 Jul; 28(7):1000-1013. PubMed ID: 33891901
[TBL] [Abstract][Full Text] [Related]
9. Targeted protein degradation: expanding the toolbox.
Schapira M; Calabrese MF; Bullock AN; Crews CM
Nat Rev Drug Discov; 2019 Dec; 18(12):949-963. PubMed ID: 31666732
[TBL] [Abstract][Full Text] [Related]
10. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
Kiely-Collins H; Winter GE; Bernardes GJL
Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
[TBL] [Abstract][Full Text] [Related]
11. Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity.
Klein VG; Bond AG; Craigon C; Lokey RS; Ciulli A
J Med Chem; 2021 Dec; 64(24):18082-18101. PubMed ID: 34881891
[TBL] [Abstract][Full Text] [Related]
12. Drugging the undruggable: targeting challenging E3 ligases for personalized medicine.
Galdeano C
Future Med Chem; 2017 Mar; 9(4):347-350. PubMed ID: 28263082
[No Abstract] [Full Text] [Related]
13. A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands.
Han B
J Biol Chem; 2020 Nov; 295(45):15280-15291. PubMed ID: 32859748
[TBL] [Abstract][Full Text] [Related]
14. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
15. A caged E3 ligase ligand for PROTAC-mediated protein degradation with light.
Kounde CS; Shchepinova MM; Saunders CN; Muelbaier M; Rackham MD; Harling JD; Tate EW
Chem Commun (Camb); 2020 May; 56(41):5532-5535. PubMed ID: 32297626
[TBL] [Abstract][Full Text] [Related]
16. Paving the way to targeting HECT ubiquitin ligases.
Zinzalla G
Future Med Chem; 2015; 7(16):2107-11. PubMed ID: 26510616
[No Abstract] [Full Text] [Related]
17. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
18. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
Anumala UR; Waaler J; Nkizinkiko Y; Ignatev A; Lazarow K; Lindemann P; Olsen PA; Murthy S; Obaji E; Majouga AG; Leonov S; von Kries JP; Lehtiö L; Krauss S; Nazaré M
J Med Chem; 2017 Dec; 60(24):10013-10025. PubMed ID: 29155568
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
Degorce SL; Tavana O; Banks E; Crafter C; Gingipalli L; Kouvchinov D; Mao Y; Pachl F; Solanki A; Valge-Archer V; Yang B; Edmondson SD
J Med Chem; 2020 Sep; 63(18):10460-10473. PubMed ID: 32803978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
